Barrett esophagus: Epidemiology, pathogenesis, diagnosis, and management

Current Problems in Surgery

Volumn 50, Issue 5, 2013, Pages 192-226

  Estores, David ^a   Velanovich, Vic ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONG UNTRANSLATED RNA; MICRORNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; TRANSCRIPTION FACTOR CDX2;

ARTICLE; ATTITUDE TO HEALTH; AUTOFLUORESCENCE IMAGING; BARRETT ESOPHAGUS; BEHAVIOR; CANCER GROWTH; CAUCASIAN; CELL TRANSDIFFERENTIATION; CHROMOENDOSCOPY; COLUMNAR EPITHELIUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMOGRAPHY; DESENSITIZATION; DIET; DIGESTIVE TRACT ENDOSCOPY; DYSPLASIA; ENDOCYTOSCOPY; ESOPHAGEAL ADENOCARCINOMA; FAMILY HISTORY; GASTROESOPHAGEAL REFLUX; HEREDITY; HISTOPATHOLOGY; HUMAN; INCIDENCE; LIFE EXPECTANCY; LIFESTYLE; LIFESTYLE MODIFICATION; LOW RISK POPULATION; MASS SCREENING; METAPLASIA; MICROBIOME; MOUTH CARCINOMA; OBESITY; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PHENOTYPE; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REFLUX ESOPHAGITIS; RISK FACTOR; SEX DIFFERENCE; SOCIAL STATUS; SQUAMOUS EPITHELIUM;

ADENOCARCINOMA; ALCOHOL DRINKING; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; DIET; DISEASE PROGRESSION; ELECTROCOAGULATION; EPITHELIUM; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS; FOOD HABITS; GASTROESOPHAGEAL REFLUX; HUMANS; IMMUNOHISTOCHEMISTRY; LIFE EXPECTANCY; MASS SCREENING; METAPLASIA; OBESITY; POPULATION SURVEILLANCE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; SMOKING; SOCIAL CLASS;

EID: 84876696234     PISSN: 00113840     EISSN: 15356337     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2013.01.004     Document Type: Article

References (164)

1. Wang K.K., Sampliner R.E. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008, 103:788-797.
2. Spechler S.J. Clinical practice. Barrett's esophagus. N Engl J Med 2002, 346:836-842.
3. Ronkainen J., Aro P., Storskrubb T., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005, 129:1825-1831.
4. Westhoff B., Brotze S., Weston A., et al. The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 2005, 61:226-231.
5. Dickman R., Kim J.L., Camargo L., et al. Correlation of gastroesophageal reflux disease symptom characteristics with long-segment Barrett's esophagus. Dis Esophagus 2006, 19:360-365.
6. Cameron A.J. Epidemiology of Barrett's esophagus and adenocarcinoma. Dis Esophagus 2002, 15:106-108.
7. Guardino J.M., Khandwala F., Lopez R., et al. Barrett's esophagus at a tertiary care center: association of age on incidence and prevalence of dysplasia and adenocarcinoma. Am J Gastroenterol 2006, 101:2187-2193.
8. Ronkainen J., Talley N.J., Storskrubb T., et al. Erosive esophagitis is a risk factor for Barrett's esophagus: a community-based endoscopic follow-up study. Am J Gastroenterol 2011, 106:1946-1952.
9. Labenz J., Nocon M., Lind T., et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorical disease. Am J Gastroenterol 2006, 101:2457-2462.
10. Malfertheiner P., Nocon M., Vieth M., et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care-the ProGERD study. Aliment Pharmacol Ther 2012, 35:154-164.
11. Stoltey J., Reeba H., Ullah N., et al. Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease?. Aliment Pharmacol Ther 2006, 25:83-91.
12. Coleman H.G., Bhat S., Murray L.J., et al. Increasing incidence of Barrett's oesophagus: a population-based study. Eur J Epidemiol 2011, 26:739-745.
13. Van Soest E.M., Dieleman J.P., Siersema P.D., et al. Increasing incidence of Barrett's esophagus in the general population. Gut 2005, 54:1062-1066.
14. Post P.N., Siersma P.D., Van Dekken H. Rising incidence of clinically evident Barrett's esophagus in the Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol 2007, 42:17-22.
15. Falk G.W., Jacobson B.C., Riddell R.H., et al. Barrett's esophagus: prevalence-incidence and etiology-origins. Ann N Y Acad Sci 2011, 1232:1-17.
16. Winberg H., Lindblad M., Lagergren J., Dahlstrand H. Risk factors and chemoprevention in Barrett's esophagus-an update. Scand J Gastroenterol 2012, 47:397-406.
17. Jung K.W., Talley N.J., Romero Y., et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population based study. Am J Gastroenterol 2011, 106:1447-1455.
18. Accessed 28.10.12. http://seer/cancer.gov/.
19. Stein D.J., El-Serag H.B., Kuczynski J., et al. The association of body mass index with Barrett's esophagus. Aliment Pharmacol Ther 2005, 22:1005-1010.
20. Crowell M.D., Bradley A., Hansel S., et al. Obesity is associated with increased 48-h esophageal acid exposure in patients with symptomatic gastroesophageal reflux. Am J Gastroenterol 2009, 104:553-559.
21. Lee H.L., Eun C.S., Lee O.Y., et al. Association between erosive esophagitis and visceral fat accumulation quantified by abdominal CT scan. J Clin Gastroenterol 2009, 43:240-243.
22. Nelsen E.M., Kirihara Y., Takahashi N., et al. Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2012, 10:728-734.
23. Cook M.B., Shaheen N.J., Anderson L.A., et al. Cigarette smoking increases the risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 2012, 142:744-753.
24. Kubo A., Block G., Queensberry C.P., et al. Effects of dietary fiber, fats, and meat intakes on the risk of Barrett's esophagus. Nutr Cancer 2009, 61:607-616.
25. Gao L., Weck M.N., Rothenbacher D., Brenner H. Body mass index, chronic atrophic gastritis and heartburn: a population-based study among 8936 older adults from Germany. Aliment Pharmacol Ther 2010, 32:296-302.
26. Khoury J.E., Chisholm S., Jamal M.M., et al. African Americans with Barrett's esophagus are less likely to have dysplasia at biopsy. Dig Dis Sci 2012, 57:419-423.
27. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011, 140:1084-1091. AGA Institute Medical Position Panel.
28. Sikkema M., de Jonge P.J., Styerberg E.W., Kuipers E.J. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010, 8:235-244.
29. Prasad G.A., Bansal A., Sharma P., Wang K.K. Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol 2010, 105:1490-1502.
30. Sharma P., Falk G.W., Weston A.P., et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006, 4:566-572.
31. Desai T.K., Krishnan K., Samala N., et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012, 61:970-976.
32. Hvid-Jensen F., Pedersen L., Drewes A.M., et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011, 365:1375-1383.
33. Buttar N.S., Wang K.K., Sebo T.J., et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001, 120:1630-1639.
34. Verbeek R.E., van Oijen M.G., ten Kate F.J., et al. Surveillence and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study. Am J Gastroenterol 2012, 107:534-542.
35. Tharavej C., Hagen J.A., Peters J.H., et al. Predictive factors of co-existing cancer in Barrett's high-grade dysplasia. Surg Endosc 2006, 20:439-443.
36. Coleman H.G., Bhat S., Johnston B.T., et al. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus. Gastroenterology 2012, 142:233-240.
37. de Jorge P.J.F., Steyerberg E.W., Kuipers E.J., et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2006, 101:1421-1429.
38. Chak A., Chen Y., Vengoechea J., et al. Variation in age at cancer diagnosis in familial versus nonfamlial Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2012, 21:376-383.
39. Chak A., Ochs-Balon A., Falk G., et al. Familiality in Barrett's esophagus adenocarcinoma of the esophagus and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 2006, 15:1668-1773.
40. Spechlar S.J., Sharma P., Souza R.F., et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011, 140:e18-e52.
41. Hur C., Wittenberg E., Nishioka N.S., Gazelle G.S. Quality of life in patients with various Barrett's esophagus associated health states. Health Qual Life Outcomes 2006, 4:45.
42. Crockett S.D., Lippmann Q.K., Dellon E.S., Shaheen N.J. Health-related quality of life in patients with Barrett's esophagus: a systematic review. Clin Gastroenterol Hepatol 2009, 7:613-623.
43. Shaheen N.J., Peery A.F., Hawes R.H., et al. Quality of life following radiofrequency ablation of dysplastic Barrett's esophagus. Endoscopy 2010, 42:790-799.
44. Fitzgerald R.C. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2006, 55:1810-1820.
45. Menard D., Arsenault P. Maturation of human fetal esophagus maintained in organ culture. Anat Rec 1987, 217:348-354.
46. Montgomery R.K., Mulberg A.E., Grand R.J. Development of the human gastrointestinal tract: twenty years of progress. Gastroenterology 1999, 116:702-731.
47. Titi M., Overhiser A., Ulusarac O., et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. Gastroenterology 2012, 143:564-566. [e1].
48. Wang D.H., Souza R.F. Biology of Barrett's esophagus and esophageal adenocarcinoma. Gastrointest Endosc Clin N Am 2011, 21:25-38.
49. Wang X., Ouyang H., Yamamoto Y., et al. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 2011, 145:1023-1035.
50. Chen H., Fang Y., Tevebaugh W., et al. Molecular mechanisms of Barrett's esophagus. Dig Dis Sci 2011, 56:3405-3420.
51. Souza R.F., Huo X., Mittal V., et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 2009, 137:1776-1784.
52. Huo X., Zhang H.Y., Zhang X.I., et al. Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. Gastroenterology 2010, 139:194-203. [e1].
53. Song S., Guha S., Liu K., et al. COX-2 induction by unconjugated bile acids involves reactive oxygen species-mediated signalling pathways in Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2007, 56:1512-1521.
54. Babar M., Ryan A.W., Anderson L.A., et al. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma. Am J Gastroenterol 2012, 107:1331-1341.
55. El-Omar E.M., Jankowski J. Editorial: genetics of Barrett's: the bigger, the better. Am J Gastroenterol 2012, 107:1342-1345.
56. Wetterstrand KA. DNA sequencing costs: data from the NHGRI Large-Scale Genome Sequencing Program. Accessed 1.10.12. http://www.genome.gov/sequencingcosts.
57. Song J.H., Meltzer S.J. MicroRNA's in the patholgenesis, diagnosis and treatment of gastroesophageal cancers. Gastroenterology 2012, 143:35-47. [e2].
58. Fassan M., Volinia S., Palatini S., et al. MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer 2011, 129:1661-1670.
59. Feber A., Xi L., Pennathur A., et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg 2011, 91:1523-1530.
60. Neumann C.S., Cooper B.T. 24 hour ambulatory oesophageal pH monitoring in uncomplicated Barrett's oesophagus. Gut 1994, 35:1352-1355.
61. Singh P., Taylor R.H., Colin-Jones D.G. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett's metaplasia is present. Am J Gastroenterol 1994, 89:349-356.
62. Fitzgerald R.C. Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?. Gut 2005, 54(suppl 1):i21-i26.
63. Richter J.E. What is the role of duodenogastroesophageal reflux in the development of BE. Ann N Y Acad Sci 2011, 1232:10-11.
64. Vaezi M.F., Richter J.E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996, 111:1192-1199.
65. Woodland P., Sifrim D. The refluxate: the impact of its magnitude, composition and distribution. Best Pract Res Clin Gastroenterol 2010, 24:861-871.
66. Johnson D.A., Winters C., Spurling T.J., et al. Esophageal acid sensitivity in Barrett's esophagus. J Clin Gastroenterol 1987, 9:23-27.
67. Fletcher J., Gillen D., Wirz A., McColl K.E. Barrett's esophagus evokes a quantitatively and qualitatively altered response to both acid and hypertonic solutions. Am J Gastroenterol 2003, 98:1480-1486.
68. Drewes A.M., Drarup A.L., Lottrup C., Frokjaer J.B. What can we tell about the etiology of BE from experimental testing of the esophagus with multimodal sensory assessment. Ann N Y Acad Sci 2011, 1232:8-9.
69. Bajpai M., Liu J., Geng X., et al. Repeated exposure to acid and bile selectively induces colonic phenotype expression in a heterogeneous Barrett's epithelial cell line. Lab Invest 2008, 88:643-651.
70. Shirvani V.N., Ouatin-Lascar R., Kaur B.S., et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000, 118:487-496.
71. Buttar N.S., Wang K.K., Leontovich O., et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002, 122:1101-1112.
72. Yang L., Lu X., Nossa C.W., et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alternations in the microbiome. Gastroenterology 2009, 137:588-597.
73. Boyce H.W. Endoscopic definitions of esophagogastric junction regional anatomy. Gastrointest Endosc 2000, 51:586-592.
74. Murray L., Watson P., Johnston B., et al. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ 2003, 327:534-535.
75. Oberg S., Johansson J., Werner J., et al. Endoscopic surveillance of columnar-lined esophagus: frequency of intestinal metaplasia detection and impact of antireflux surgery. Ann Surg 2001, 234:619-626.
76. Sharma P., Dent J., Armstrong D., et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006, 131:1392-1399.
77. Vahabzadeh B., Seetharam A.B., Cook M.B., et al. Validation of the Prague C & M criteria for the endoscopic grading of Barrett's esophagus by gastroenterology trainees: a multicenter study. Gastrointest Endosc 2012, 75:236-241.
78. Abrams J.A., Kapel R.C., Lindberg G.M., et al. Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol 2009, 7:736-742.
79. Bennett C., Vakil N., Bergman J., et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma based on a Delphi process. Gastroenterology 2012, 143:336-346.
80. ASGE PIVI Committee. Imaging in Barrett's esophagus PIVI. Accessed 29.10.12. http://www.asge.org/WorkArea/showcontent.aspv?id=15028.
81. Gupta N., Gaddam S., Wani S.B., et al. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett's esophagus. Gastrointest Endosc 2012, 76:531-538.
82. Kiesslich R. Advanced imaging in endoscopy. Eur Gastroenterol Hepatol Rev 2009, 5:22-25.
83. High-resolution magnification endoscopes. Gastrointest Endosc 2009, 69:399-407. ASGE Technology Assessment Committee.
84. Ferguson D.D., DeVault K.R., Krishna M., et al. Enhanced magnification directed biopsies do not increase the detection of intestinal metaplasia in patients with GERD. Am J Gastroenterol 2006, 101:1611-1616.
85. Curvers W.L., Bohmer C.J., Mallaut-Hent R.L., et al. Mucosal morphology in Barrett's esophagus: interobserver agreement and role of narrow-band imaging. Endoscopy 2008, 40:799-805.
86. Curvers W.L., Bergman J.J. Multimodality imaging in Barrett's esophagus: looking longer, seeing better, and recognizing more. Gastroenterology 2008, 135:297-299.
87. Sharma P., Hawes R.H., Bansal A., et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: a prospective, international, randomized controlled trial. Gut 2012, [epub ahead of print].
88. Curvers W., Baak L., Kiesslich R., et al. Chromoendoscopy and narrow band imaging compared with high resolution magnification endoscopy in Barrett's esophagus. Gastroenterology 2008, 134:670-674.
89. McGill S., Soetikno R., Kaltenbach T. Image-enhanced endoscopy practice. Can J Gastroenterol 2009, 23:741-746.
90. Costamagna G., Marchese M. Progress in endoscopic imaging of gastrointestinal tumor. Eur Rev Med Pharmacol Sci 2010, 14:272-276.
91. Curvers W.L., Herrero L.A., Wallace M.B., et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology 2010, 139:1106-1114.
92. Mannath J., Banks M. Emerging technologies in endoscopic imaging. F1000 Med Rep 2012, 4:3. [epub 2012 Feb 1].
93. Evans J.A., Nishioka N.S. The use of optical coherence tomography in screening and surveillance of Barrett's esophagus. Clin Gastroenterol Hepatol 2005, 3:S8-S11.
94. Kiesslich R., Gossner L., Goetz M., et al. In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol 2006, 4:979-987.
95. Neumann H., Fuchs F.S., Vieth M., et al. In vivo imaging by endocytoscopy. Aliment Pharmacol Ther 2011, 33:1183-1193.
96. Pohl H., Koch M., Khalifa A., et al. Evaluation of endocytoscopy in the surveillance of patients with Barrett's esophagus. Endoscopy 2007, 39:492-496.
97. Chang J.Y., Talley N.J., Locke G.R., et al. Population screening for Barrett's esophagus: a prospective randomized pilot study. Mayo Clin Proc 2011, 86:1174-1180.
98. Gralnek I.M., Adler S.N., Yassin K., et al. Detecting esophageal disease with second-generation capsule endoscopy: initial evaluation of the PillCam ESO 2. Endoscopy 2008, 40:275-279.
99. Harrison R., Perry I., Haddadin W., et al. Dectection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 2007, 102:1154-1161.
100. Riddell R.H., Goldman H., Ransohoff D.F., et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983, 14:931-968.
101. Goldblum J.R. Controversies in the diagnosis of Barrett esophagus and Barrett-related dysplasia: one pathologist's perspective. Arch Pathol Lab Med 2010, 134:1479-1484.
102. Downs-Kelly E., Mendelin J.E., Bennett A.E., et al. Poor interobserver agreement in the distribution of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies. Am J Gastroenterol 2008, 103:2333-2340.
103. Omer Z.B., Ananthakrishnan A.N., Nattinger K.J., et al. Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol 2012, 10:722-727.
104. Beales I.L., Vardi I., Dearman L. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 2012, [epub ahead of print].
105. Kastelein F., Spaander M.C., Beirmann K., et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011, 141:2000-2008.
106. Soni A., Sampliner R.E., Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?. Am J Gastroenterol 2000, 95:2086-2093.
107. Inadomi J.M., Sampliner R., Lagergren J., et al. Screening and surveillance for Barrett's esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003, 138:176-186.
108. Taylor J.B., Rubenstien J.H. Meta-analysis of the effects of symptoms of gastroesophageal reflux in the risk of Barrett's esophagus. Am J Gastroenterol 2010, 105:1729-1730.
109. Shaheen N.J. Should women with heartburn undergo screening upper endoscopy for prevention of cancer?. Am J Gastroenterol 2011, 106:261-263.
110. Crockett S.D., Lipkus I.M., Bright S.D., et al. Overutilization of endoscopic surveillance in non-dysplastic Barrett's esophagus: a multicenter study. Gastrointest Endosc 2012, 75:23-31.
111. Rubenstein J.H., Saini S.D., Kuhn L., et al. Influence of malpractice history on the practice of screening and surveillance for Barrett's esophagus. Am J Gastroenterol 2008, 103:842-849.
112. Raftopoulos S.C., Efthymiou M., May G., Marcon N. Dysplastic Barrett's epithelium in cirrhosis: a treatment dilemma. Am J Gastroenterol 2011, 106:1724-1726.
113. Inadomi J.M., Somsouk M., Madanick R.D., et al. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009, 136:2101-2114.
114. Velanovich V. How Many Esophageal Cancers Need to be Prevented to Make Ablation of Barrett's Esophagus Cost-Effective? 2007 Annual Scientific Session of the Society of American Gastrointestinal and Endoscopic Surgeons. Las Vegas, NV; 2007.
115. Ferguson M.K., Dunkin A. Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and non-surveyed patients. J Gastrointest Surg 2002, 6:29-35.
116. Courrech Staal E.F.W., van Sandick J.W., van Tinteren H., et al. Health-related quality of life in long-term esophageal cancer survivors after potentially curvative treatment. J Thorac Cardiovasc Surg 2010, 140:777-783.
117. Rees J.R., Lao-Sirieix P., Wong A., Fitzgerald R.C. Treatment for Barrett's esophagus. Cochrane Database Syst Rev 2010, 20(1):CD 004060.
118. Fleischer D.E., Odze R., Overholt B.F., et al. The case for endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett's esophagus. Dig Dis Sci 2010, 55:1918-1931.
119. Garside R., Pitt M., Somerville M., et al. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modeling. Health Technol Assess 2006, 10:1-142.
120. Sharma P., McQuaid K., Dent J., et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004, 127:310-330.
121. Barbiere J.M., Lyratzopoulos G. Cost-effectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review. Gastroenterology 2009, 137:1869-1876.
122. Cooper B.T., Chapman W., Neumann C.S., et al. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitor up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 2006, 23:727-733.
123. Vieth M., Schubert B., Lang-Schwarz K., et al. Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study. Endoscopy 2006, 38:1201-1205.
124. Horwhat J.D., Baroni D., Maydonovitch C., et al. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol 2006, 101:1-10.
125. Wong T., Tian J., Nager A.B. Barrett's surveillance identifies patients with early esophageal adenocarcinoma. Am J Med 2010, 123:462-467.
126. Bampton P.A., Schloithe A., Bull J., et al. Improving surveillance for Barrett's oesophagus. BMJ 2006, 332:1320-1323.
127. Oelschlager B.K., Barreca M., Chang L., et al. Clinical and pathologic response of Barrett's esophagus to laparoscopic antireflux surgery. Ann Surg 2003, 238:458-464.
128. Attwood S.E., Lundell L., Hatlebakk J.G., et al. Medical or surgical management of GERD patients with Barrett's esophagus: the LOTUS trial 3-year experience. J Gastrointest Surg 2008, 12:1646-1654.
129. Biertho L., Dallemagne B., Dewandre J.-M., et al. Laparoscopic treatment of Barrett's esophagus: long-term results. Surg Endosc 2007, 21:11-15.
130. Chang E.Y., Morris C.D., Seltman A.K., et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett's esophagus: a systematic review. Ann Surg 2007, 246:11-21.
131. Gurski R.R., Peters J.H., Hagen J.A., et al. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 2003, 196:706-712.
132. Bowers S.P., Mattar S.G., Smith C.D., et al. Clinical and histologic follow-up after antireflux surgery for Barrett's esophagus. J Gastrointest Surg 2002, 6:532-538.
133. Lagergren J., Ye W., Lagergren P., Lu Y. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology 2010, 138:1297-1301.
134. AGA Institute Medical Position Position Panel American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011, 140:1084-1091.
135. National Institute for Health and Clinical Excellence. CG 106 Barrett's oesophagus-ablative therapy: NICE guideline. Accessed 14.10.12. http://guidance.nice.org.uk/CG106.
136. Stefandis D., Hope W.W., Kohn G.P., et al. Guidelines for surgical treatment of gastroesophageal reflux disease. Surg Endosc 2010, 24:2647-2669.
137. Wang K.K., Song L.M.W.K., Buttar N., et al. Barrett's esophagus after photodynamic therapy: risk of cancer development during long-term follow-up. Gastroenterology 2004, 126(suppl 2):A50.
138. Menon D., Stafinski T., Wu H., et al. Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy. BMC Gastroenterol 2010, 10:111.
139. Overholt B.F., Wang K.K., Burdick J.S., et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007, 66:460-468.
140. Prasad G.A., Wang K.K., Buttar N.S., et al. Predictors of stricture formation after photodynamic therapy for high grade dysplasia in Barrett's esophagus. Gastrointest Endosc 2007, 65:60-66.
141. Allison H., Banchs M.A., Borris P.A., Guelrud M. Long-term remission of nondysplastic Barrett's esophagus after multipolar electrocoagulation ablation: report of 139 patients with 10 years of follow-up. Gastrointest Endosc 2011, 73:651-658.
142. Kovacs B.J., Chen Y.K., Lewis T.D., et al. Successful reversal of Barrett's esophagus with multipolor electrocoagulation despite inadequate acid suppression. Gastrointest Endosc 1999, 49:547-553.
143. Li Y.M., Li L., Yu C.H., et al. A systematic review and meta-analysis of the treatment for Barrett's esophagus. Dig Dis Sci 2008, 53:2837-2846.
144. Bright T., Watson D.I., Tam W., et al. Randomized trial of argon plasma coagulation versus endoscopic surveillance for Barrett's esophagus after antireflux surgery: late results. Ann Surg 2007, 246:1016-1020.
145. Dunkin B.J., Martinez J., Bejarano P.A., et al. Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device (BARRx). Surg Endosc 2006, 20:125-130.
146. Smith C.D., Bejarano P.A., Melvin W.S., et al. Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system. Surg Endosc 2007, 21:560-569.
147. Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus: initial results and lessons learned. Surg Endosc 2009, 23:2175-2180.
148. Wani S., Puli S.R., Shaheen N.J., et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009, 104:502-513.
149. Shaheen N.J., Sharma P., Overholt B.F., et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009, 360:2277-2288.
150. National Institute for Health and Clinical Excellence. Epithelial radiofrequency ablation for Barrett's oesophagus. NICE 2010. Accessed 14.10.12. http://guidance.nice.org.uk/IPG344.
151. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology. 2011;141:460-468.
152. Vaccaro B.J., Gonzalez S., Ponevos J.M., et al. Dectection of intestinal metaplasia after successful eradication of Barrett's esophagus with radiofrequency ablation. Dig Dis Sci 2011, 56:1996-2000.
153. Titi M., Overhiser A., Ulusarac O., et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. Gastroenterology 2012, 143:564-566.
154. Johnston M.H., Eastone J.A., Horwhat J.D., et al. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc 2005, 62:842-848.
155. Dumot J.A., Vargo J.J., Falk G.W., et al. An open-label prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc 2009, 70:635-644.
156. Shaheen N.J., Greenwald B.D., Peery A.F., et al. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010, 71:680-685.
157. Bisschops R. Optimal endoluminal treatment of Barrett's esophagus: integrating novel strategies into clinical practice. Expert Rev Gastroenterol Hepatol 2011, 4:319-333.
158. Hubbard N., Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett's esophagus in patients with fundoplications. Surg Endosc 2007, 21:625-628.
159. Goers T.A., Leao P., Cassera M.A., et al. Ablation and laparoscopic reflux operative results in more effective and efficient treatment of Barrett's esophagus. J Am Coll Surg 2011, 213:486-492.
160. O'Connell K., Velanovich V. Effects of Nissen fundoplication on endoscopic endoluminal radiofrequency ablation of Barrett's esophagus. Surg Endosc 2011, 25:830-834.
161. Krishnan K., Pandolfino J.E., Kahrilas P.J., et al. Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology 2012, 143:576-581.
162. Rice T.W., Sontag S.J. Debate: esophagectomy is the treatment of choice for high grade dysplasia in Barrett's esophagus. Am J Gastroenterol 2006, 101:2177-2184.
163. Williams V.A., Watson T.J., Herbella F.A., et al. Esophagectomy for high-grade dysplasia is safe, curative and results in good alimentary outcome. J Gastrointest Surg 2007, 11:1589-1597.
164. Djarv T., Lagegren J., Blazeby J.M., Lagegren P. Long-term health-related quality of life following surgery for oesophageal cancer. Br J Surg 2008, 95:1121-1126.